Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2008 3
2010 3
2011 2
2012 3
2013 3
2014 1
2015 2
2016 6
2017 2
2018 3
2020 1
2021 3
2022 1
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.
Laurent C, Flores M, Chartier L, Huet S, Bolen CR, Venstrom JM, Chassagne-Clément C, Dartigues-Cuilléres P, Charlotte F, Tesson B, Salles G, Morschhauser F, Xerri L. Laurent C, et al. Among authors: chartier l. Br J Haematol. 2023 Aug;202(3):686-689. doi: 10.1111/bjh.18881. Epub 2023 May 22. Br J Haematol. 2023. PMID: 37218065 Free PMC article. No abstract available.
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.
Thieblemont C, Altmann B, Frontzek F, Renaud L, Chartier L, Ketterer N, Récher C, Poeschel V, Fitoussi O, Held G, Casasnovas O, Haioun C, Morschhauser F, Glass B, Mounier N, Tilly H, Rosenwald A, Ott G, Lenz G, Molina T, Ziepert M, Schmitz N. Thieblemont C, et al. Among authors: chartier l. Blood Adv. 2023 Aug 8;7(15):3968-3977. doi: 10.1182/bloodadvances.2022008888. Blood Adv. 2023. PMID: 36716220 Free PMC article. Clinical Trial.
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
Aubrais R, Bouabdallah K, Chartier L, Herbaux C, Banos A, Brice P, Sibon D, Schiano JM, Cluzeau T, Laribi K, Le Calloch R, Bellal M, Delapierre B, Daguindau N, Amorim S, Agbetiafa K, Chauchet A, Besson C, Durot E, Bonnet C, Fouillet L, Bijou F, Tournilhac O, Gaulard P, Parrens MC, Damaj G. Aubrais R, et al. Among authors: chartier l. Blood Adv. 2023 Oct 10;7(19):5733-5742. doi: 10.1182/bloodadvances.2022008524. Blood Adv. 2023. PMID: 36477770 Free PMC article.
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma.
Thieblemont C, Chartier L, Dührsen U, Vitolo U, Barrington SF, Zaucha JM, Vercellino L, Gomes Silva M, Patrocinio-Carvalho I, Decazes P, Viailly PJ, Tilly H, Berriolo-Riedinger A, Casasnovas O, Hüttmann A, Ilyas H, Mikhaeel NG, Dunn J, Cottereau AS, Schmitz C, Kostakoglu L, Paulson JN, Nielsen T, Meignan M. Thieblemont C, et al. Among authors: chartier l. Blood Adv. 2022 Dec 13;6(23):5995-6004. doi: 10.1182/bloodadvances.2021006923. Blood Adv. 2022. PMID: 36044385 Free PMC article.
Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells.
Galtier J, Vercellino L, Chartier L, Olivier P, Tabouret-Viaud C, Mesguich C, Di Blasi R, Durand A, Raffy L, Gros FX, Madelaine I, Meignin V, Mebarki M, Rubio MT, Feugier P, Casasnovas O, Meignan M, Thieblemont C. Galtier J, et al. Among authors: chartier l. Haematologica. 2023 Jan 1;108(1):171-180. doi: 10.3324/haematol.2021.280550. Haematologica. 2023. PMID: 35678029 Free PMC article.
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.
Ghesquières H, Rossi C, Cherblanc F, Le Guyader-Peyrou S, Bijou F, Sujobert P, Fabbro-Peray P, Bernier A, Belot A, Chartier L, Fornecker LM, Baldi I, Bouabdallah K, Laurent C, Oberic L, Morineau N, Le Gouill S, Morschhauser F, Haioun C, Damaj G, Guidez S, Labouré G, Fitoussi O, Lebras L, Gressin R, Salles G, Ysebaert L, Monnereau A. Ghesquières H, et al. Among authors: chartier l. BMC Public Health. 2021 Mar 2;21(1):432. doi: 10.1186/s12889-021-10433-4. BMC Public Health. 2021. PMID: 33653294 Free PMC article.
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Le Gouill S, Ghesquières H, Oberic L, Morschhauser F, Tilly H, Ribrag V, Lamy T, Thieblemont C, Maisonneuve H, Gressin R, Bouhabdallah K, Haioun C, Damaj G, Fornecker L, Bouhabdallah R, Feugier P, Sibon D, Cartron G, Bonnet C, André M, Chartier L, Ruminy P, Kraeber-Bodéré F, Bodet-Milin C, Berriolo-Riedinger A, Brière J, Jais JP, Molina TJ, Itti E, Casasnovas RO. Le Gouill S, et al. Among authors: chartier l. Blood. 2021 Apr 29;137(17):2307-2320. doi: 10.1182/blood.2020008750. Blood. 2021. PMID: 33211799 Free article.
40 results